NANETS: Pancreastatin Predicts Survival in Patients with Neuroendocrine Tumors
Higher pancreastatin associated with worse survival times in surgically treated small bowel (SBNET) and pancreatic neuroendocrine tumors (PNETs).
Higher pancreastatin associated with worse survival times in surgically treated small bowel (SBNET) and pancreatic neuroendocrine tumors (PNETs).
Lymph node ratio (LNR) may offer better survival prediction over the current measure for patients with carcinoid neuroendocrine tumors.
Octreotide has demonstrated promising results vs. a subset of carcinoid tumors, despite a lower overall response rate.
Tumor-specific mutations are common in high-grade neuroendocrine tumors.
A 3-marker immunohistochemistry panel helps determine the primary site of malignancy in metastatic neuroendocrine tumors.